

The United States vs. Other Countries: Availability of New Medicines Varies

The Most Favored Nation rule would set U.S. prices for medicines covered under Medicare Part B based on the pricing policies of 22 foreign governments – many of which set prices artificially low, resulting in severe access restrictions for patients.

		New Medicines Available	Average Delay in Availability of New Medicines
	Iceland*	N/A	N/A
	Israel*	N/A	N/A
	Luxembourg*	N/A	N/A
	New Zealand	20%	30 months
	Korea	35%	28 months
	Australia	39%	20 months
	Ireland	41%	20 months
	Belgium	44%	22 months
	Canada	46%	15 months
	Switzerland	46%	17 months
	Spain	49%	23 months
	France	50%	18 months
	Finland	51%	16 months
	Japan	51%	16 months
	Italy	51%	20 months
	Netherlands	53%	7 months
	Norway	54%	13 months
	Denmark	54%	12 months
	Sweden	54%	8 months
	Austria	58%	11 months
	United Kingdom	59%	11 months
	Germany	63%	10 months
	United States	87%	0-3 months

Source: PhRMA analysis of IQVIA Analytics Link and U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) data. June 2020.
Note: New active substances approved by FDA, EMA and/or PMDA and first launched in any country between January 1, 2011, and December 31, 2019. *Data for Iceland, Israel and Luxembourg are currently unavailable.